Glenmark becomes the first company to launch Indacaterol + Mometasone FDC for asthma in India
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Glenmark is the first company in India to market the innovative FDC of Indacaterol
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Subscribe To Our Newsletter & Stay Updated